A L Tutt
Overview
Explore the profile of A L Tutt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
416
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glennie M, Honeychurch J, French R, Tutt A
Methods Mol Med
. 2011 Feb;
40:85-97.
PMID: 21337085
Monoclonal antibodies (mAbs) appear to offer many benefits for the treatment of cancer and in particular lymphoma (1). They are natural products that can be made with precise specificity and...
2.
Chowdhury F, Tutt A, Chan C, Glennie M, Johnson P
J Immunol Methods
. 2010 Sep;
363(1):1-8.
PMID: 20869964
As part of a Phase I chimeric anti-CD40 monoclonal antibody clinical trial, two enzyme-linked immunosorbent assays (ELISAs) were developed for secondary endpoints: 1) for the pharmacokinetic (PK) monitoring of serum...
3.
Hampson G, Ward T, Cummings J, Bayne M, Tutt A, Cragg M, et al.
J Immunol Methods
. 2010 Jun;
360(1-2):30-8.
PMID: 20547164
Rituximab is a chimeric anti-CD20 monoclonal antibody that has revolutionised the treatment of many B-cell malignancies, and is now increasingly being used in non-malignant conditions such as auto-immune disorders. Serum...
4.
Todryk S, Tutt A, Green M, Smallwood J, Halanek N, Dalgleish A, et al.
J Immunol Methods
. 2001 Feb;
248(1-2):139-47.
PMID: 11223075
Tumour vaccines provide an important focus of current cancer research and are often based on the premise that although T-cells do respond naturally to certain tumours, this is usually weak...
5.
Wong W, Vakis S, Ayre K, Ellwood C, Howell W, Tutt A, et al.
Scand J Rheumatol
. 2000 Nov;
29(5):282-7.
PMID: 11093593
Rheumatoid arthritis (RA) T cells respond poorly to conventional mitogens. We have examined the proliferative and cytokine responses of T cells to a synthetic trispecific antibody (Tsab) directed against CD2,...
6.
Honeychurch J, Tutt A, Valerius T, Heijnen I, van de Winkel J, Glennie M
Blood
. 2000 Nov;
96(10):3544-52.
PMID: 11071653
CD64 (FcgammaRI) receptors represent highly potent trigger molecules for activated polymorphonuclear cells (PMN) and mediate lysis of a range of tumors in the presence of appropriate monoclonal antibodies. An huCD64...
7.
Stockmeyer B, Dechant M, van Egmond M, Tutt A, Sundarapandiyan K, Graziano R, et al.
J Immunol
. 2000 Nov;
165(10):5954-61.
PMID: 11067958
CD20 Abs induce clinical responses in lymphoma patients, but there are considerable differences between individual patients. In (51)Cr release assays with whole blood as effector source, RAJI cells were effectively...
8.
French R, Chan H, Tutt A, Glennie M
Nat Med
. 1999 May;
5(5):548-53.
PMID: 10229232
CD40 is essential in enabling antigen-presenting cells to process and present antigen effectively to T cells. We demonstrate here that when antibody against CD40 is used to treat mice with...
9.
Tutt A, French R, Illidge T, Honeychurch J, McBride H, Penfold C, et al.
J Immunol
. 1998 Sep;
161(6):3176-85.
PMID: 9743386
Despite the recent success of mAb in the treatment of certain malignancies, there is still considerable uncertainty about the mechanism of action of anti-cancer Abs. Here, a panel of rat...
10.
Wurflein D, Dechant M, Stockmeyer B, Tutt A, Hu P, Repp R, et al.
Cancer Res
. 1998 Jul;
58(14):3051-8.
PMID: 9679970
Promising results from clinical trials have led to renewed interest in effector mechanisms operating in antibody-based therapy of leukemia and lymphoma. We tested a panel of B-cell antibodies from the...